MXPA04005782A - Metodos para inducir la ovulacion usando un modulador de nivel camp no polipeptido. - Google Patents

Metodos para inducir la ovulacion usando un modulador de nivel camp no polipeptido.

Info

Publication number
MXPA04005782A
MXPA04005782A MXPA04005782A MXPA04005782A MXPA04005782A MX PA04005782 A MXPA04005782 A MX PA04005782A MX PA04005782 A MXPA04005782 A MX PA04005782A MX PA04005782 A MXPA04005782 A MX PA04005782A MX PA04005782 A MXPA04005782 A MX PA04005782A
Authority
MX
Mexico
Prior art keywords
methods
level modulator
inducing ovulation
polypeptide
camp level
Prior art date
Application number
MXPA04005782A
Other languages
English (en)
Inventor
Mckenna Sean
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of MXPA04005782A publication Critical patent/MXPA04005782A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invencion se relaciona a metodos para inducir la ovulacion en un huesped femenino el cual comprende la administracion de un modulador de nivel de adenosimonofosfato ciclico (cAMP) no polipeptido al huesped femenino. En otro aspecto, la invencion proporciona la administracion especifica del inhibidor de fosfodiesterasa antes a la fase lutea del ciclo ovulatorio del huesped. Un modulador de nivel de cAMP no polipeptido preferido incluye inhibidores de fosfodiesterasa, particularmente inhibidores de isoformas de fosfodiesterasa 4.
MXPA04005782A 2001-12-14 2001-12-14 Metodos para inducir la ovulacion usando un modulador de nivel camp no polipeptido. MXPA04005782A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2001/014730 WO2003051344A1 (en) 2001-12-14 2001-12-14 Methods of inducing ovulation_using a non-polypeptide camp level modulator

Publications (1)

Publication Number Publication Date
MXPA04005782A true MXPA04005782A (es) 2004-09-13

Family

ID=8164724

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005782A MXPA04005782A (es) 2001-12-14 2001-12-14 Metodos para inducir la ovulacion usando un modulador de nivel camp no polipeptido.

Country Status (18)

Country Link
US (1) US7507707B2 (es)
EP (2) EP1908463B1 (es)
JP (1) JP4532115B2 (es)
KR (2) KR101056916B1 (es)
CN (1) CN1582146A (es)
AT (2) ATE526013T1 (es)
AU (1) AU2002217111B2 (es)
BR (2) BR0117198A (es)
CA (1) CA2469939C (es)
DE (1) DE60130813T2 (es)
DK (2) DK1908463T3 (es)
EA (1) EA011213B1 (es)
ES (1) ES2293965T3 (es)
IL (3) IL162506A0 (es)
MX (1) MXPA04005782A (es)
PT (2) PT1908463E (es)
UA (1) UA80418C2 (es)
WO (1) WO2003051344A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
MXPA05010373A (es) * 2003-04-01 2005-12-05 Applied Research Systems Inhibidores de fosfodiesterasas en infertilidad.
JP2007517828A (ja) * 2004-01-17 2007-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 気道の疾患を治療するための置換プテリジンの使用
DE102004002557A1 (de) * 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
EP1915155A1 (en) * 2005-08-03 2008-04-30 Boehringer Ingelheim International GmbH Dihydropteridinones in the treatment of respiratory diseases
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
WO2009019205A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
CN103169699B (zh) * 2011-12-22 2014-11-12 中国农业大学 来曲唑在用于制备成年牛超数排卵药物中的应用
CN104968664A (zh) * 2012-12-12 2015-10-07 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的并环化合物
JP2016525532A (ja) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄異形成症候群の処置
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087615A (en) * 1989-03-17 1992-02-11 Applied Research Systems Ars Holding N.V. Novel method of ovulation induction in humans
US5710170A (en) * 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
GB9603723D0 (en) * 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
AP1147A (en) 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
DE69738949D1 (de) 1996-05-20 2008-10-09 Darwin Discovery Ltd Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren
BR9709105A (pt) 1996-05-20 1999-08-03 Darwin Discovery Ltd Sulfonamidas de quinolina como inibidoras de tnf e como inobidoras de pde-iv
BR9709113A (pt) 1996-05-20 1999-08-03 Darwin Discovery Ltd Benzofurano carboxamidas e seu uso terapêutico
EP0934307B1 (en) 1996-06-19 2011-04-27 Aventis Pharma Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
EA002274B1 (ru) 1996-06-25 2002-02-28 Пфайзер Инк. Призводные замещенного индазола и их применение в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и фактора некроза опухоли (фно)
GB9614718D0 (en) 1996-07-12 1996-09-04 Bayer Ag 3-ureido-pyridofurans and -pyridothiophenes
ES2196308T3 (es) 1996-10-02 2003-12-16 Janssen Pharmaceutica Nv Derivado de 2-cianoiminoimidazol que inhiben la pde iv.
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
EP0946541B1 (en) 1996-11-06 2003-07-30 Darwin Discovery Limited Quinolines and their therapeutic use
JP3237109B2 (ja) * 1996-12-13 2001-12-10 田辺製薬株式会社 医薬組成物
US6472425B1 (en) * 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
IL139027A0 (en) * 1998-04-23 2001-11-25 Asta Medica Ag Method for the treatment of fertility disorders
KR20010043828A (ko) * 1998-05-26 2001-05-25 에바-마리아 시마-메이어, 얼설라 멜져, 마거, 하르트만 ｃＡＭＰ-증강 화합물 단독 또는 감수분열-자극 화합물하나 이상과의 조합에 의한 불임 치료 방법
EP1086096B1 (de) * 1998-06-10 2003-07-23 ALTANA Pharma AG Benzamide mit tetrahydrofuranyloxy-substituenten als inhibitoren der phosphodiesterase 4
US6316472B1 (en) * 1999-05-13 2001-11-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
TR200909479T2 (tr) * 1999-08-21 2012-02-21 Nycomed Gmbh Sinerjistik kombinasyon.
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
CA2405711A1 (en) * 2000-04-17 2001-10-25 Bioimage A/S Live cell procedures to identify compounds modulating intracellular distribution of phosphodiesterase (pde) enzymes
JP4371295B2 (ja) * 2000-05-19 2009-11-25 メルク セローノ ソシエテ アノニム 医薬として活性な化合物およびその使用方法
ATE332708T1 (de) * 2000-06-06 2006-08-15 Glaxo Group Ltd Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält
US6953774B2 (en) * 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US20020065324A1 (en) * 2000-08-11 2002-05-30 Stephen Palmer Methods of inducing ovulation
MXPA05010373A (es) * 2003-04-01 2005-12-05 Applied Research Systems Inhibidores de fosfodiesterasas en infertilidad.

Also Published As

Publication number Publication date
BR0117198A (pt) 2004-10-26
EP1908463A2 (en) 2008-04-09
DK1908463T3 (da) 2011-11-28
ATE526013T1 (de) 2011-10-15
WO2003051344A1 (en) 2003-06-26
PT1463493E (pt) 2008-01-04
EA200400808A1 (ru) 2004-12-30
IL205106A (en) 2013-02-28
KR20090009336A (ko) 2009-01-22
AU2002217111A1 (en) 2003-06-30
EP1463493B1 (en) 2007-10-03
ES2293965T3 (es) 2008-04-01
DE60130813T2 (de) 2008-07-03
UA80418C2 (en) 2007-09-25
EP1908463B1 (en) 2011-09-28
EP1908463A3 (en) 2009-11-25
AU2002217111B8 (en) 2003-06-30
EP1463493A1 (en) 2004-10-06
IL162506A (en) 2012-03-29
BRPI0117198B1 (pt) 2018-03-13
JP4532115B2 (ja) 2010-08-25
ATE374606T1 (de) 2007-10-15
JP2005516924A (ja) 2005-06-09
US20050148501A1 (en) 2005-07-07
EA011213B1 (ru) 2009-02-27
IL162506A0 (en) 2005-11-20
CN1582146A (zh) 2005-02-16
KR20040075004A (ko) 2004-08-26
KR101056916B1 (ko) 2011-08-12
CA2469939A1 (en) 2003-06-26
DK1463493T3 (da) 2008-02-04
AU2002217111B2 (en) 2007-05-31
DE60130813D1 (de) 2007-11-15
PT1908463E (pt) 2011-12-19
US7507707B2 (en) 2009-03-24
IL205106A0 (en) 2010-11-30
CA2469939C (en) 2012-06-19

Similar Documents

Publication Publication Date Title
MXPA04005782A (es) Metodos para inducir la ovulacion usando un modulador de nivel camp no polipeptido.
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
HUP0303016A3 (en) Xanthine phosphodiesterase v inhibitors, process for their preparation and pharmaceutical compositions containing them and their use
HK1096673A1 (en) Compositions useful as inhibitors of protein kinases
ATE245648T1 (de) 1h-pyrazolo(3,4-d)pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellen
MY132106A (en) New pyridazin-3(2h)-one derivatives
MXPA04004779A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.
DK1303632T3 (da) Galactomannan-oligosaccharid og fremgangsmåde til fremstilling samt anvendelse heraf
IL156704A0 (en) Use of an adenosine a3 receptor agonist for inhibition of viral replication
NO322013B1 (no) Farmasoytisk enhetsdoseringsblanding, samt anvendelse derav
GB0000561D0 (en) Treatment of diabetic ulcers
GB0111497D0 (en) Therapeutic methods
ES2168860T3 (es) Procedimiento de sincronizacion y/o de intercambio de datos para ordenadores seguros, de alta disponibilidad, y dispositivo adecuado para ello.
GB0028245D0 (en) New therapeutic use
BRPI0416202A (pt) formulações inibidoras de fosfodiesterase v
WO2002003993A3 (en) Use of inhibitors to multidrug resistance protein 5 (mrp5) to enhance intracellular levels of cyclic nucleotides
UA34213A (uk) Спосіб прогнозування післяпологових метроендометритів
YU87302A (sh) Inhibitori 11-beta-hidroksi steroidne dehidrogenaze, tip 1
GEP20094596B (en) Compositions comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction
MY127989A (en) Treatment of neuropathy

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration
HC Change of company name or juridical status